A Study of Etrasimod in Adults With Moderate-to-Severe Atopic Dermatitis, Who Have Tried Prior Systemic Treatments for Atopic Dermatitis

A Phase 2/3, Two-Part Study to Evaluate the Efficacy and Long-Term Safety With Oral Etrasimod, 2 mg, Once Daily in Adult Participants With Moderate-to-Severe Atopic Dermatitis With a History of Prior Systemic Treatment Failure.